🇺🇸 FDA
Patent

US 7300654

Method of treating corneal transplant rejection in high risk keratoplasty patients

granted A61KA61K31/00A61K31/7088

Quick answer

US patent 7300654 (Method of treating corneal transplant rejection in high risk keratoplasty patients) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/00, A61K31/7088, A61K45/06